Opens in a new tab
Investigational treatment For PTSD

Introducing the Redefine Study

Evaluating the efficacy, safety, and tolerability of COMP360 in participants with
post-traumatic stress disorder
Adults aged 18+
PTSD Diagnosis

About The Redefine Study

The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder
(PTSD) symptoms when administered alongside monitoring and support from a trained study team.
Our clinic has helped hundreds of individuals in Minnesota and across the Midwest find relief from conditions that often feel unrelenting.

Study Overview:

Condition
Post-traumatic Stress Disorder (PTSD)
Recruitment Status
Recruiting
Intervention
COMP360 psilocybin
Principal Investigator
Manoj Doss, DO
A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

Eligibility Criteria

Participant criteria for eligibility in this study.
*Even if you may not meet all the criteria, feel free to reach out using the Join Study button

Key Inclusion Criteria:

  1. Participant must be 18 years of age or older.
  2. Participant has a diagnosis of PTSD.
  3. Participants taking antidepressants have been on a stable dose.
  4. Participant was diagnosed with PTSD at least 6 months ago.

Key Exclusion Criteria:

  1. Current or previous diagnosis of bipolar disorder, schizophrenia, antisocial personality disorder, borderline personality disorder, OCD, or anorexia nervosa.
  2. Severe alcohol use disorder or moderate/severe substance use disorder within six months.
  3. Psychedelic use within 12 months.
  4. Cardiovascular conditions, including stroke, myocardial infarction, or uncontrolled hypertension.
  5. Unwillingness to consent to audio/video recording.

Participant Commitment

This section outlines the commitment required for this study.

  • Participation is expected to last 55 to 62 weeks.

  • Up to 22 in-person clinic visits.

  • 5 remote appointments via video call

  • In-person treatment visits last 6 to 8 hours.

How to Join Studies at IIT

  1. Follow the link below to 'sign up' for inquiring study participants.
  2. After completion of criteria questions, please enter in your contact information and submit the form.
  3. Following submission, medical records review, and eligibility a research study coordinator will reach out for an inital study screening call.
See if You're Eligible
We will begin enrolling for this trial momentarily, stay tuned!

Contact Us and Learn More

Email: [email protected]
Phone: (651) 280–8774

Important Study Links:

*Note that Cybin has been rebranded to Helus Pharma in January of 2026
ClinicalTrials.gov ID:  NCT07570654
clinicaltrials.gov/study/NCT07570654
COMPASS Pathways - Study Page
redefineptsdstudy.com/
COMPASS Pathways
compasspathways.com